ReviewCancers2025
Clinical Aspects of Cutaneous Metastasis from Non-Cutaneous Primary Tumors.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous metastases (CMs) represent an uncommon but clinically significant manifestation of advanced malignancies, originating from both solid and non-solid cancers. This review explores the clinical characteristics and prognostic implications of CMs. For solid cancers, CMs are most frequently associated with primary malignancies of the breast, lung, and gastrointestinal tract, presenting as nodules, plaques, or ulcerative lesions. In contrast, CMs from non-solid cancers, such as hematologic malignancies, often exhibit distinct patterns, including diffuse infiltrates or erythematous plaques, mimicking inflammatory dermatoses. Clinical features, as well as dermoscopy, may help, but diagnostic confirmation relies on histopathological evaluation and immunohistochemical studies, which are essential for determining the primary source of the malignancy. Clinically, CMs often signify a poor prognosis, necessitating prompt recognition and tailored management to improve patient outcomes. This comprehensive review aims to enhance clinical understanding and awareness of CMs to facilitate early diagnosis and optimized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.